OCA
BBIO icon

Octagon Capital Advisors’s BridgeBio Pharma BBIO Stock Holding History

Octagon Capital Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-441,600
Closed -$12.1M – 36
2024
Q4 		$12.1M Sell
441,600
-110,400
-20% -$2.85M 1.99% 21
2024
Q3 		$14.1M Sell
552,000
-138,000
-20% -$3.62M 2.19% 16
2024
Q2 		$17.5M Hold
690,000
– – 2.75% 10
2024
Q1 		$21.3M Sell
690,000
-16,800
-2% -$571K 2.56% 12
2023
Q4 		$28.5M Sell
706,800
-264,839
-27% -$7.95M 4.57% 6
2023
Q3 		$25.6M Sell
971,639
-247,561
-20% -$7.03M 3.94% 10
2023
Q2 		$21M Sell
1,219,200
-118,960
-9% -$1.79M 2.92% 9
2023
Q1 		$22.2M Buy
1,338,160
+404,417
+43% +$4.72M 3.19% 10
2022
Q4 		$7.12M Hold
933,743
– – 1.11% 20
2022
Q3 		$9.28M Hold
933,743
– – 1.6% 15
2022
Q2 		$8.48M Sell
933,743
-1,333,743
-59% -$11.2M 2.26% 9
2022
Q1 		$23M Buy
2,267,486
+500,000
+28% +$5.13M 4.98% 5
2021
Q4 		$29.5M Buy
1,767,486
+1,198,072
+210% +$50.7M 5.74% 5
2021
Q3 		$26.7M Buy
569,414
+188,486
+49% +$10.1M 6.57% 5
2021
Q2 		$23.2M Buy
+380,928
New +$21.8M 4.81% 4

Other funds holding BBIO

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Octagon Capital Advisors's BBIO Position: Q1 2025 in Review

Octagon Capital Advisors sold out of BridgeBio Pharma (BBIO) in Q1 2025, closing a stake of 441,600 shares — an estimated $12.1M sold.

Octagon Capital Advisors first reported a position in BBIO in Q2 2021 and held it in 15 quarters. The position peaked at $29.5M in Q4 2021. 304 funds tracked by Wall St. Rank hold BBIO as of Q1 2025.

  • Octagon Capital Advisors reported no remaining BridgeBio Pharma position as of Q1 2025 after selling out during the quarter.
  • Octagon Capital Advisors sold 441,600 BridgeBio Pharma shares in Q1 2025, an estimated $12.1M.
  • Octagon Capital Advisors first reported a position in BridgeBio Pharma in Q2 2021 and held it in 15 quarters.
  • Octagon Capital Advisors's BridgeBio Pharma position peaked at $29.5M in Q4 2021.
  • 304 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2025.

Based on Octagon Capital Advisors's 13F filing for Q1 2025, filed 15 May 2025.